NCT04562922 (LEO) is a Phase 2 clinical trial of Lifemel in Neutropenia, sponsored by VitalMel.

Who is sponsoring NCT04562922?

NCT04562922 is sponsored by VitalMel.

What drugs are being tested in NCT04562922?

Interventions in NCT04562922: Lifemel.

What condition does NCT04562922 study?

NCT04562922 studies Neutropenia, Adverse Event.

Is NCT04562922 still recruiting?

NCT04562922 is currently completed. Last updated 24 September 2020.

Last reviewed 2020-09-24 · How we verify

NCT04562922: LEO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy

Completed Phase 2 Last updated 24 September 2020

What this trial tests

Phase 2 trial testing Lifemel in Neutropenia in 39 participants. Completed in 4 April 2016.

Timeline

11 November 2013

Primary endpoint
26 May 2014

4 April 2016

Quick facts

Lead sponsor	VitalMel
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	39
Start date	11 November 2013
Primary completion	26 May 2014
Estimated completion	4 April 2016

Drugs / interventions tested

Lifemel

Conditions studied

Neutropenia — all drugs for Neutropenia →
Adverse Event — all drugs for Adverse Event →

Sponsor

VitalMel

Who can join

18 and older, any sex, with Neutropenia or Adverse Event. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

LEO trial was designed to assess the benefit of administering LifeMel to prevent myelotoxicity in patients affected by solid neoplasm undergoing antiblastic chemotherapy treatment at low to moderate risk of febrile neutropenia. Secondary endpoints of LEO trial were assessing impact of LifeMel in preventing anaemia and thrombocytopenia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Simon's two-stage design trial evaluating the potential role of a kind of honey in preventing chemotherapy-hematopoietic toxicities.
Sponghini AP, Rondonotti D, Platini F, Cena T, et al · · 2021 · cited 2× · PMID 34522641 · DOI 10.1016/j.jtcme.2021.04.005

Verify or expand the search:

Other recruiting trials for Neutropenia

Currently open trials in the same condition.

NCT07434063 — Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection · recruiting
NCT07066085 — Serial Blood Count Study · EARLY_PHASE1 · recruiting
NCT06537726 — Breath Analysis for the Detection of Invasive Fungal Infections · recruiting
NCT06145321 — Continuous Versus Bolus Administration of G-CSF in Children With Cancer · Phase 4 · active not recruiting
NCT06422533 — Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04562922 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VitalMel
Last refreshed: 24 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04562922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing